ReviewPhytotherapy research : PTR2026
Immunomodulatory Properties of Withania somnifera: Regulation of Innate Immune Cells and Clinical Implications.
Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Withania somnifera (L.) Dunal (WS), commonly known as Ashwagandha, is a prominent medicinal herb in Ayurveda, with extensive therapeutic potential attributed to its diverse phytochemical profile. This review critically examines the immunomodulatory properties of WS, focusing on innate immune cell populations, including neutrophils, eosinophils, macrophages, dendritic cells, and natural killer (NK) cells. Bioactive constituents, particularly withanolides and withaferin A derived mainly from roots and leaves, orchestrate immune responses through modulation of cytokine networks, enhancement of phagocytic activity, and attenuation of oxidative stress. WS constituents regulate key signaling pathways, including ERK, NF-κB, and JAK/STAT, at transcriptional and translational levels. WS exhibits a dual immunoregulatory role by enhancing innate immune cell functionality while suppressing pathological inflammation in allergic and chronic inflammatory disorders. However, critical gaps persist in elucidating its molecular mechanisms, establishing phytochemical standardization, and defining context-specific dosing regimens. Collectively, current evidence positions WS as a promising candidate for the management of autoimmune, infectious, and inflammatory diseases. However, it further highlights the need for rigorous mechanistic studies and well-designed clinical trials to enable its integration into evidence-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.